Fleisher AS, Schneider JA, Beach TG, Bedell BJ, Zehntner SP, Clark CM, Krautkramer MP, Pontecorvo MJ, Joshi A, Skovronsky DM.
Update on florbetapir F 18 (18F-AV-45) PET clinical studies.
Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
Abstract: Avid Radiopharmaceuticals is currently conducting a phase III clinical study of subjects at the end of
life with and without neurodegenerative dementia. A planned interim analysis of the first six subjects brought to
autopsy has been performed comparing histopathology to quantitative and qualitative assessments of amyloid
Subjects who were ≥18 years old and willing to consent to a brain autopsy were admitted to the study if they
had a life expectancy of Of the six subjects, 4 had a clinical diagnosis at the time of imaging of AD, one had a clinical diagnosis of
Parkinson’s disease with dementia (PDD), and one had no clinical evidence of dementia. The mean age was
76 (range 47-86). Histopathology, CERAD neuritic plaque scores, florbetapir PET SUVr values, and visual ratings
of grey matter retention will be presented and compared for the six autopsy cases.